SubsidieMeestersA Novel ‘Radiotherapy from Within’ Platform Technology for the Targeted Treatment of Solid Tumours Called ‘BAT-90’
BetaGlue's BAT-90 is a personalized radiotherapy platform that targets solid tumors like HCC and PDAC, minimizing off-target effects through percutaneous administration, showing promising safety and effectiveness.
Projectdetails
Introduction
BetaGlue is developing an innovative "radiotherapy from within," personalized and cost-effective anti-tumoural platform technology called BAT-90.
Technology Overview
BAT-90 maximizes the therapeutic index of loco-regional treatment by eliminating off-target radiation dose in a simple and easy-to-use product.
Target Patient Population
The product aims to provide a radiotherapeutic treatment option for a range of solid tumour types, including:
- Unresectable hepatocellular carcinoma (HCC)
- Locally advanced and borderline resectable pancreatic cancer (PDAC) patients
In the first-line setting, there exists a major unmet clinical need for these patients.
Administration Method
Through the percutaneous administration of BAT-90 under radiological guidance (usually ultrasound), BAT-90 overcomes the accessibility and off-target side effect limitations of:
- External beam radiotherapy
- Forms of brachytherapy
- Proton beam radiotherapy
- Trans-arterial radio-embolisation
- Microwave ablation
Clinical Studies
BAT-90 has already demonstrated safety and preliminary effectiveness in first-in-human clinical studies.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.499.999 |
| Totale projectbegroting | € 7.135.825 |
Tijdlijn
| Startdatum | 1-4-2024 |
| Einddatum | 31-12-2025 |
| Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- BETAGLUE TECHNOLOGIES SPApenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Innovative approach to an Individualised T-Cell Immunotherapy for cancer, using Personalised Tumour Trained Lymphocytes (pTTL) that is reliable, cost-effective, scalable and easy to implementNEOGAP's project aims to develop a personalized T cell therapy for solid tumors using machine learning and neoantigen stimulation, with a focus on safety and biomarker exploration in colorectal cancer trials. | EIC Accelerator | € 2.500.000 | 2023 | Details |
Novel peptide-based therapeutics for reprogramming the tumour stroma extracellular matrix using molecular modelling and computational engineeringThe project aims to develop TAX2, a novel peptide therapy targeting the tumor microenvironment to inhibit solid tumor progression and enhance immunotherapy efficacy, with a focus on ovarian cancer. | EIC Accelerator | € 2.434.790 | 2025 | Details |
LIACFLASH: a life changing IOeRT technology for oncology careLIACFLASH is an innovative IOeRT system leveraging the FLASH effect to deliver high radiation doses that effectively target tumors while minimizing damage to surrounding healthy tissue. | EIC Accelerator | € 2.499.962 | 2022 | Details |
Immune Photo-Activated Cancer Therapy for the Treatment of Upper Tract Urothelial Cancer (UTUC) and other solid tumoursPadeliporfin-VTP therapy offers a minimally invasive treatment for UTUC by using laser-activated photosensitizers to eliminate tumors while preserving organ function, aiming for regulatory approval and market entry. | EIC Accelerator | € 2.498.730 | 2024 | Details |
The OVAL study for VB-111 treatment of platinum-resistant ovarian cancerVBL Therapeutics aims to finalize a Phase 3 trial for VB-111, a novel anti-cancer gene therapy targeting tumor blood supply and immune response, starting with ovarian cancer treatment. | EIC Accelerator | € 2.500.000 | 2022 | Details |
Innovative approach to an Individualised T-Cell Immunotherapy for cancer, using Personalised Tumour Trained Lymphocytes (pTTL) that is reliable, cost-effective, scalable and easy to implement
NEOGAP's project aims to develop a personalized T cell therapy for solid tumors using machine learning and neoantigen stimulation, with a focus on safety and biomarker exploration in colorectal cancer trials.
Novel peptide-based therapeutics for reprogramming the tumour stroma extracellular matrix using molecular modelling and computational engineering
The project aims to develop TAX2, a novel peptide therapy targeting the tumor microenvironment to inhibit solid tumor progression and enhance immunotherapy efficacy, with a focus on ovarian cancer.
LIACFLASH: a life changing IOeRT technology for oncology care
LIACFLASH is an innovative IOeRT system leveraging the FLASH effect to deliver high radiation doses that effectively target tumors while minimizing damage to surrounding healthy tissue.
Immune Photo-Activated Cancer Therapy for the Treatment of Upper Tract Urothelial Cancer (UTUC) and other solid tumours
Padeliporfin-VTP therapy offers a minimally invasive treatment for UTUC by using laser-activated photosensitizers to eliminate tumors while preserving organ function, aiming for regulatory approval and market entry.
The OVAL study for VB-111 treatment of platinum-resistant ovarian cancer
VBL Therapeutics aims to finalize a Phase 3 trial for VB-111, a novel anti-cancer gene therapy targeting tumor blood supply and immune response, starting with ovarian cancer treatment.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Development of innovative proton and neutron therapies with high cancer specificity by 'hijacking' the intracellular chemistry of haem biosynthesis.NuCapCure aims to develop novel cancer treatments for glioblastoma by utilizing custom-made drugs through biosynthesis to enhance proton and neutron therapies for better targeting and efficacy. | EIC Pathfinder | € 5.972.875 | 2024 | Details |
Treatment planning assessment for the Optiflux radiosurgery systemDit project ontwikkelt een innovatieve radiotherapie met sub-MeV X-stralen voor nauwkeurige tumorbehandeling en minder schade aan omliggende organen. | Mkb-innovati... | € 20.000 | 2021 | Details |
Catalysis for Cancer Treatment.Cat4CanCenter aims to develop innovative metal-based catalysts and lipid nanoparticle delivery systems to create effective therapies for glioblastoma, overcoming current treatment challenges. | ERC Synergy ... | € 10.603.994 | 2024 | Details |
2D Material-Based Multiple Oncotherapy Against Metastatic Disease Using a Radically New Computed Tomography ApproachPERSEUS aims to develop a novel nanotechnology-based cancer therapy that activates under CT imaging to treat deep-seated, drug-resistant tumors with minimal side effects. | EIC Pathfinder | € 2.740.675 | 2023 | Details |
PRO CellecTPan Cancer T ontwikkelt een innovatieve TCR-gebaseerde therapie voor hard-to-treat kankers, met een strategisch plan om de commerciële haalbaarheid en waarde te maximaliseren. | Mkb-innovati... | € 20.000 | 2021 | Details |
Development of innovative proton and neutron therapies with high cancer specificity by 'hijacking' the intracellular chemistry of haem biosynthesis.
NuCapCure aims to develop novel cancer treatments for glioblastoma by utilizing custom-made drugs through biosynthesis to enhance proton and neutron therapies for better targeting and efficacy.
Treatment planning assessment for the Optiflux radiosurgery system
Dit project ontwikkelt een innovatieve radiotherapie met sub-MeV X-stralen voor nauwkeurige tumorbehandeling en minder schade aan omliggende organen.
Catalysis for Cancer Treatment.
Cat4CanCenter aims to develop innovative metal-based catalysts and lipid nanoparticle delivery systems to create effective therapies for glioblastoma, overcoming current treatment challenges.
2D Material-Based Multiple Oncotherapy Against Metastatic Disease Using a Radically New Computed Tomography Approach
PERSEUS aims to develop a novel nanotechnology-based cancer therapy that activates under CT imaging to treat deep-seated, drug-resistant tumors with minimal side effects.
PRO CellecT
Pan Cancer T ontwikkelt een innovatieve TCR-gebaseerde therapie voor hard-to-treat kankers, met een strategisch plan om de commerciële haalbaarheid en waarde te maximaliseren.